Different phenotypes of lattice corneal dystrophy type I in patients with 417C>T (R124C) and 1762A>G (H572R) mutations in TGFBI (BIGH3) by Romero, Pablo et al.
Different phenotypes of lattice corneal dystrophy type I in patients
with 417C>T (R124C) and 1762A>G (H572R) mutations in
TGFBI (BIGH3)
Pablo Romero,1,2 Mauricio Moraga,3 Luisa Herrera3
1Depto. de Oftalmología, Hospital Clínico “José Joaquín Aguirre,” Universidad de Chile, Santiago, Chile; 2Servicio de
Oftalmología, Hospital del Salvador, Universidad de Chile, Santiago, Chile; 3Programa de Genética Humana, ICBM, Facultad de
Medicina, Universidad de Chile, Santiago, Chile
Purpose:  To  describe  clinical  data  and  to  characterize  mutations  in  the  transforming  growth  factor  beta-induced
(TGFBI) gene in patients from three unrelated Chilean families with lattice corneal dystrophy type I (LCDI).
Methods: Snellen acuity tests, anterior segment slit lamp examinations, dilated fundus evaluations, and tonometry were
performed for seven patients—five females and two males belonging to three unrelated families—affected with lattice
corneal dystrophy Type I. Genomic DNA was also extracted from peripheral leukocytes from the seven patients and four
healthy relatives. The 417C>T mutation (R124C) was screened using PCR-RFLP for the seven patients and four healthy
relatives. Exons 11, 12, 13, and 14 were sequenced in one patient not carrying the mutation in codon 124. Comparison of
phenotype to genotype was performed.
Results: The seven patients studied exhibited LCDI in both eyes, most of which were symmetric. Affected individuals
demonstrated progression from central subepithelial needlelike deposits and polymorphic anterior stromal opacities. The
age at onset of symptoms varied between six to 15 years old in Family One; the patient in Family Two was five years old
and the patient in Family Three was 21 years old. Visual acuity varied from 1.0 to 0.05. Two patients, aged 50 and 45
years, underwent penetrating keratoplasty in both eyes, and two patients, aged 47 and 24 years, underwent penetrating
keratoplasty in one eye. The only patient in Family Three exhibited a somewhat distinct phenotype, with yellowish
discoloration in the anterior stroma and fewer, but thicker lattice lines than the patients in Families One and Two. Screening
for the mutation C>T at the nucleotide position 417 (R124C) in exon 4 in the three families revealed the heterozygous
R124C mutation in Families One and Two. In Family Two, the mutation was a de novo mutation, as neither parent was
a carrier. Screening by sequencing analysis for mutation in exons 11, 12, 13, and 14 in the affected patient in Family Three
revealed a heterozygous A1762G mutation (H572R) in exon 13.
Conclusions: This is the second report of the 417C>T mutation and the first report of 1762 A>G mutation (H572R) in
Chilean patients. The H572R mutation identified is associated with a distinct lattice corneal dystrophy type I phenotype.
Lattice  corneal  dystrophy  (LCD)  is  one  of  the  most
common  inherited  corneal  diseases,  characterized  by  the
accumulation of amyloid throughout the middle and anterior
stroma, forming a network of branching refractile lines. It
develops with recurrent corneal erosion and keratoplasty is
frequently required [1]. Four distinct subtypes of LCD have
been  described:  types  I  (OMIM  122200),  II  (OMIM
105120), III (OMIM 204870), and IIIA (OMIM 608471).
Lattice corneal dystrophy type I is an early onset autosomal
dominant dystrophy with variable clinical expression [2].
Thus  far,  few  mutations  have  been  described  in  the
transforming growth factor beta-induced (TGFBI) gene as
causative of LCD type I. The mutation list includes R124C,
V505D, L518P, V539D, A546D, P551Q, L569R, H572R, and
V625D [3,4]; the mutation C>T at the nucleotide position 417
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(R124C) in exon 4 is the most frequent throughout the world
[5-16].
The TGFBI gene is located in chromosome region 5q31
[5,17]  and  encodes  for  transforming  growth  factor-beta-
induced  protein  ig-h3  (TGFBIp),  formerly  known  as
keratoepithelin  (KE),  an  extracellular  matrix  protein
expressed in many tissues and in the corneal epithelium [18,
19]. It is a 68 kDa protein, composed of 682 amino acids, and
contains four internal repeat domains (FAS) homologous to
one  another  and  to  fasciclin-1  of  Drosophila  [20].
Transforming  growth  factor-beta-induced  protein  ig-h3  is
presumably involved in cell adhesion and migration of various
cell types, including epithelial cells, fibroblasts, osteoblasts,
endothelial cells, and vascular smooth muscle cells [21-23].
Although  TGFBIp  is  ubiquitously  expressed,  its
accumulation in corneal dystrophies is restricted to the cornea,
and  no  other  tissues  are  affected  [24].  Neither  TGFBIp’s
normal function nor the molecular mechanisms underlying the
pathogenesis of corneal dystrophy are yet understood. In the
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extracellular matrix.
In this study, we report three unrelated Chilean families
with LCDI. Two families carry 417C>T (R124C) and one
carries a 1762A>G (H572R) mutation in TGFBI. The clinical
characteristics of a lattice corneal dystrophy caused by these
two mutations are described.
METHODS
Patients: All examinations were performed according to the
tenets of the Declaration of Helsinki and the present study was
approved by the ethics committee of the Clinical Hospital of
the University of Chile. All patients were informed about the
study  and  gave  signed  consent.  Three  index  cases  were
identified  during  ophthalmic  examination  at  the  Clinical
Hospital of the University of Chile. After obtaining informed
consent, seven affected and four unaffected members from
three Chilean families with lattice corneal dystrophy were
enrolled. Families One and Two were not related and the last
names  and  family  histories  suggest  Spanish  origin.  The
proband of Family Three was adopted and we do not have any
information about his biological family.
Clinical  evaluations:  All  participants  received  a  detailed
clinical examination that included best-corrected visual acuity
(BCVA) according to the best line of Snellen acuity, slit lamp
biomicroscopy,  color  cornea  photography,  pneumatic
tonometry  (CT  8  Computerized  tonometer;  Topcon  Ltd,
Tokyo,  Japan),  and  dilated  fundus  examination.
Autorefractometry  measurement  and  keratometry  were
performed (model RM-A7000). We considered high myopia
when the refractive error was greater than -6.0 diopters.
The  LCD  type  1  diagnosis  was  based  on  clinical
examination. The corneal phenotype of all index patients was
assessed  by  slit  lamp  examination  and  the  review  of
biomicroscopic photographs by an investigator who did not
know the genetic status.
The  lesions  were  considered  to  be  synchronic  if  the
patients perceived the first symptoms in the second eye within
a month of perceiving them in the first. All individuals with
corneal  commitment  were  considered  clinically  affected.
Patients were classified in degrees of severity according to
best-corrected  vision,  the  number  of  lesions,  and  corneal
commitment (Table 1).
Molecular  genetic  analysis:  Peripheral  blood  (5  ml)  was
collected  from  seven  patients  and  four  unaffected  family
members and genomic DNA was isolated [25]. The 417C>T
(R124C) mutation in exon 4 of TGFBI was analyzed in all
TABLE 1. CLINICAL FEATURES IN THE AFFECTED PATIENTS.
         
Best-corrected
       vision
       
Case Age Gender Status Age of
onset
(years)
OD OS Synchronic Symmetry Degree according
to best-corrected
vision
Degree according
to corneal
commitment
Family 1
III-1 81 F Affected 14 0.1 0.05 Yes Yes Bad in both eyes 4 in both eyes
IV-10 53 M Affected 15 0.7 0.5 Yes Yes Very Good in the
right eye, Good in
the left eye
3 in both eyes
IV-13 50 F Affected 10 0.1 0.2 Yes Yes Bad in both eyes 4 in both eyes
V-17 22 F Affected 15 1.0 1.0 Yes Yes Very good in both
eyes
1 in both eyes
V-19 27 F Affected 6 0.8 0.7 Yes Yes Very good in both
eyes
3 in both eyes
Family 2
II-1 25 F Affected 5 0.3 0.4 Yes Yes Bad in the rigth
eye, Intermediate
in the left eye
4 in the right eye
and 3 in the left eye
Family 3
I-1 52 M Affected 21 0.3 0.2 Yes Yes Bad in both eyes 4 in both eyes
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The phenotypic features of seven patients from the three families affected by lattice corneal dystrophy type I are shown. Corneal
phenotypes were assessed by slit lamp examination. The lesions were considered to be synchronic if the patients perceived the
first symptoms in the second eye within a month after they appeared in the first eye. The degree of severity according to best-
corrected vision was classified as: very good (>0,6), good (<=0,6 and >0,4), intermediate (<=0,4 and >0,33), and bad (<=0,33).
The degree of severity according to corneal commitment was classified as follows: 1) without lesions, 2) subepithelial, white-
grayish opacities, 3) refractile lattice lines, and 4) corneal edema or penetrating keratoplasty. The following abbreviations were
used male (M), female (F), right eye (OD), and left eye (OS).patients  and  controls  using  polymerase  chain  reaction-
restriction fragment length polymorphisms (PCR-RFLP), as
previously  described  [26].  Briefly,  genomic  DNA  was
amplified by PCR using the primers TGFBI F1: 5′-CTT TCC
CAC ATG CCT CCT CGT-3′ (forward) and TGFBI Rmut:
5′-TCT CAG GCC TCA GCT TCT CCC TGC-3′ (reverse).
The PCR amplification was performed as follows: the initial
step of denaturation at 95 °C for 5 min was followed by 35
cycles  of  1  min  each,  including  denaturation  at  95  °C,
annealing at 58 °C, elongation at 72 °C, and a final extension
at 72 °C for 5 min. The 221 base pair (bp) products obtained
were digested using the PstI restriction enzyme (Fermentas,
Vilnius, Lithuania) for 3 h at 37 °C. Fragments were resolved
by electrophoresis in 3.5% agarose gel, stained with ethidium
bromide,  and  visualized  under  ultraviolet  light.  After
digestion, the “T” mutant allele consisted of three fragments
of  21,  76,  and  124  base  pairs  and  the  “C”  normal  allele
consisted of two fragments of 97 and 124 base pairs.
Exons 11, 12, 13, and 14 of TGFBI were amplified by
PCR using the primers and conditions described previously
[27]. The primers encompassed the entire exons and short
segments of the flanking introns. The PCR amplifications
were performed as follows: the initial step of denaturation at
95 °C for 5 min was followed by 35 cycles of 1 min each,
including denaturation at 95 °C, annealing at either 58 °C
(exon 11, 12, and 14) or 60 °C (exon 13), elongation at 72 °C,
and a final extension at 72 °C for 5 min. The PCR products
were sent for sequencing at Macrogen® DNA Sequencing
Service (Macrogen, Seoul, Korea).
Paternity was confirmed by microsatellite typing of 15
short tandem repeat (STR) loci and Amelogenin using the
AmpF/STR  Identifiler  PCR  amplification  kit  (Applied
Biosystems,  Foster  City,  CA)  under  the  recommended
conditions.
RESULTS
Clinical findings: Three unrelated index cases were identified
during ophthalmic examination at the Clinical Hospital of the
University of Chile, Santiago, Chile. The pedigrees of their
families were delineated, revealing there were eleven living
cases of affected patients in Family One and only one affected
member in each of Families Two and Three (Figure 1). We
examined some available members of the three families. The
phenotypic features of five affected individuals of Family One
and the affected individuals of Families Two and Three are
summarized in Table 1.
Family One: The pedigree of Family One is shown in Figure
1A. This was a four-generation family with eleven living
affected individuals. Based on an interview with patient III-1,
LCD could be traced back over two generations, indicating
that there were two dead subjects with a history of LCDI (I-1
and II-2). The presence of LCD type I in the six continuous
generations indicates an autosomal dominant transmission.
Six relatives of the proband were clinically examined. Four
were affected by LCD type I (three females and one male) and
two were not affected (one female and one male), as shown
in  the   pedigree  (Figure 1A).   The   phenotypic   features   of 
affected family members are summarized in Table 1.
Case V-19—The proband, a 27-year-old woman, began
with episodes of acute ocular pain, redness, and photophobia
at  six  years  of  age.  The  frequency  and  severity  of  these
episodes increased coincident with a gradual deterioration of
vision  in  both  eyes.  Slit  lamp  examination  showed  the
presence of large, typical fine branching lattice lines in the
anterior stroma of both eyes (Figure 2A,B). A clear area was
preserved around the corneal-scleral limbus. She showed a
network  of  linear  opacities  associated  with  other  smaller
opaque spots and refractile lattice lines. No vascularization of
the  cornea  was  observed.  Central  corneal  sensation  was
reduced. Best-corrected vision was 0.8 in the right eye (OD)
and 0.7 in the left eye (OS).
Case III-1—The proband’s maternal grandmother, an
81-year-old woman, began having symptoms at 14 years of
age. She underwent penetrating keratoplasty in the right eye
at age 47. Slit lamp examination revealed clinical signs of the
recurrence of LCD type 1 in the corneal grafts of the right eye;
the  corneal  graft  exhibited  a  network  of  linear  opacities
associated  with  other  smaller  opaque  spots  and  refractive
lattice lines and diffuse anterior stromal opacity (not shown).
Her left eye revealed irregularity of the epithelial surface with
subepithelial and anterior stromal scarring, resulting in diffuse
clouding of the central cornea (Figure 2C). Peripheral corneal
vascularization was observed in both eyes. Visual acuity was
0.1 (OD) and 0.05 (OS).
Case IV-10—The proband’s maternal uncle, a 53-year-
old man, began with episodes of recurrent corneal erosions at
15 years of age. Slit lamp examination showed the presence
of a network of linear opacities associated with other smaller
opaque spots and refractile lattice lines in both eyes (OD,
Figure 2D). No vascularization of the cornea was observed.
He also had high myopia in both eyes. Best-corrected vision
was 0.7 in the right eye (OD) and 0.5 in the left eye (OS).
Case  IV-13—The  proband’s  mother,  a  50-year-old
woman, began having episodes of acute ocular pain, redness,
and  photophobia  at  10  years  of  age.  The  frequency  and
severity of these episodes increased coincident with a gradual
deterioration of vision in both eyes. At 32 years of age, she
was diagnosed with lattice corneal dystrophy. She underwent
keratoplasty in her left eye at age 45 and in her right eye at
age  47.  When  she  was  initially  examined  at  the  Clinical
Hospital of the University of Chile, slit lamp examination
revealed clinical signs of the recurrence of LCD type 1 in the
corneal grafts of both eyes. She had bilateral blurred vision;
both  corneal  grafts  showed  a  network  of  linear  opacities
associated  with  other  smaller  opaque  spots  and  refractive
lattice lines and diffuse anterior stromal opacity (Figure 2E).
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was OD: 0.1 and OS: 0.2.
Case V-17—The proband’s maternal first cousin, a 22-
year-old woman, began with episodes of recurrent corneal
erosions  at  15  years  of  age.  However,  an  ophthalmic
examination  revealed  no  lesions  characteristic  of  lattice
corneal dystrophy, i.e., no typical fine branching lattice lines
or vascularization of the cornea were observed. Best-corrected
vision was 1.0 in both eyes.
Family  Two:  This  was  a  two-generation  family  with  one
affected individual in the second generation. The pedigree of
this family is shown in Figure 1B.
Case II-1—The proband, a 25-year-old women, began
with episodes of recurrent corneal erosions at five years of
age.  She  also  had  high  myopia  in  both  eyes.  Slit  lamp
examination showed the presence of elevated subepithelial
opacities, fine lattice lines, diffuse “ground glass” haze in the
anterior stroma, and corneal grafts (Figure 2F). Best-corrected
vision  was  0.3  (OD)  and  0.4  (OS)  (Table1).  No
vascularization of the cornea was observed. Central corneal
sensation  was  decreased.  She  underwent  penetrating
keratoplasty in the right eye at age 24. She was diagnosed with
Urrets-Zavalia syndrome in the right eye one month after the
surgery (Figure 2G). She did not have a family history of
corneal diseases.
Case I-1 and case I-2—The proband’s parents, who had
no history of recurrent corneal erosions, had a completely
normal ophthalmic examination. Best-corrected vision was
1.0 in both eyes for each parent. We also examined three other
family  members  (cases  II-2,  II-3  y  II-4).  All  were
phenotypically normal.
Family Three: This was a two-generation family with one
affected individual in the first generation. The pedigree of this
family is shown in Figure 1C.
Case I-1—The proband, a 52-year-old man, was adopted
and had no knowledge of his parents' ocular status. He began
with episodes of recurrent corneal erosions at 21 years of age.
He underwent penetrating keratoplasty in the left eye at age
50 and in the right eye at age 51. Slit lamp examination
performed before surgery showed the presence of elevated
subepithelial  opacities,  stromal  thick  lattice  lines,  diffuse
“ground glass” haze, and a yellowish discoloration in the
Figure 1. Pedigrees of three families affected by Lattice Corneal Dystrophy type 1. A: Pedigree showing six consecutive generations of affected
members. B: Pedigree showing two generations with just one affected member in the second generation. C: Pedigree showing two generations
with just one affected member in the first generation. Autosomal dominant transmission of the disease is evident in the first family; the other
two families are not informative about the transmission pattern since they are too small and include only one affected individual each. Since
LCDI has a dominant transmission and the parents are not affected, the pedigree of Family Two suggests a de novo mutation. The arrows at
the lower left of the symbol indicate the probands, open and filled symbols indicate unaffected and affected individuals respectively, squares
indicate males, and circles indicate females. Asterisks indicate members of the family who underwent clinical examination and molecular
analyses.
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vision was 0.3 (OD) and 0.2 (OS) (Table 1). Vascularization
of the cornea and decreased central corneal sensation was
observed in both eyes. We also examined his son, who was
phenotypically normal.
Dilated fundus examination and tonometry were normal
in all members of the three families.
Molecular genetic analyses: Exon 4 of TGFB1 in individuals
III-1, IV-10, IV-13, V-15, V-17, V-19, and V-21 of Family
One, I-1, I-2, and II-1 of Family Two, and I-1 of Family Three
Molecular Vision 2010; 16:1601-1609 <http://www.molvis.org/molvis/v16/a172> © 2010 Molecular Vision
1605
Figure 2. Photographs of the cornea from six individuals examined using slit lamp examination. Slit lamp photographs of patient V-19 of
Family One at 27 years of age show opacities in the central stroma and linear forms in the left cornea (A and B; A: OD and B: OS). The image
of case III-1 shows irregularity of the epithelial surface with subepithelial and anterior stromal scarring in the left eye (C). The image of case
IV-10 revealed the presence of a network of linear opacities associated with polymorphic anterior stromal opacities in the right eye (D). The
image of case IV-13 at 50 years of age shows opacities in the central stroma and linear forms in the left cornea (E). The image of case II-1 of
Family Two at age 25 shows a network of linear opacities associated with other smaller opaque spots and refractile lattice lines in the left eye
(F) and the right eye shows penetrating keratoplasty with characteristic mydriasis of Urrets-Zavalia syndrome (G). The photographs of case
I-1 of Family Three at 52 years of age show thick lattice lines and yellowish discoloration in the anterior stroma, resulting in clouding of the
central cornea (H and I).were analyzed using PCR-RFLP and were digested using the
PstI restriction enzyme, as previously described [26]. The
results indicate that all affected individuals of Family One
carry the heterozygous missense mutation 417C>T (R124C)
in TGFBI. This mutation was not present in healthy controls.
The same mutation was detected in individual II-1 of Family
Two, but was absent in both parents (Figure 3). Paternity was
confirmed, indicating the R124C mutation was a de novo
mutation. Individual I-1 of Family Three does not carry that
mutation.
Exons 11, 12, 13, and 14 of TGFBI of the proband of
Family  Three  were  further  analyzed  by  sequencing.  The
sequence  of  exon  13  revealed  a  heterozygous  missense
mutation 1762A>G that changed histidine to arginine at codon
572  (H572R).  This  mutation  was  observed  in  both  direct
(Figure 4) and reverse sequences (not shown).
DISCUSSION
We described the phenotypic characteristics and the mutations
in TGFBI in seven patients in three families affected with
LCDI. We used a combined strategy to identify the mutations.
First, we performed a rapid screening based on PCR-RFLP to
detect  the  common  417C>T  mutation  [26].  When  that
mutation  was  not  detected,  we  looked  for  other  putative
mutations in exons 11, 12, 13, and 14 of TGFBI where other
common mutations have been reported [3]. That screening
was performed using PCR, followed by direct sequencing of
both strands.
Figure 3. Screening for the 417C>T (R124C) mutation using polymerase chain reaction-restriction fragment length polymorphism. Exon 4
was amplified from individuals III-1, IV-10, IV-13, V-15, V-17, V-19, and V21 of Family One, I-1, I-2, and II-1 of Family Two, and I-1 of
Family Three and the PCR product were digested with PstI restriction enzyme. After digestion, the products were analyzed using 3.5% agarose
gel electrophoresis. Allele 417C generates two DNA fragments of 124 and 97 base pairs, and allele 417T generates three DNA fragments of
124, 76, and 21 base pairs. The 21 base pair fragment cannot be observed in this kind of agarose gel electrophoresis. Patients III-1, IV-10,
IV13, V17, and V-19 of Family One and II-1 of Family Two are heterozygous for the 417C>T mutation, and individuals V-15 and V21 of
Family One, I-1 and I-2 of Family Two, and I-1 of Family Three do not carry the mutation.
Figure 4. Direct sequencing of exon 13
of the TGFBI gene in the proband of
Family Three (individual I-1). The DNA
sequence around the codon for histidine
572  (CAC)  of  the  TGFBI  gene  is
presented.  The  sequence  shows  a
heterozygous,  single-base  A→G
transition at nucleotide 1762, resulting
in the replacement of histidine (CAC)
with  arginine  (CGC)  (H572R).  The
codon  numbers  and  the  amino  acid
sequence are indicated at the top of the
figure.
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heterozygous 417C>T mutation in the hotspot of exon 4 in all
affected subjects of Families One and Two. This mutation
causes the substitution of arginine 124 for cysteine (R124C)
in the first FAS domain. Families One and Two were not
related, indicating that the mutations at the codon 124 hotspot
arose separately and therefore they do not represent a founder
effect. Moreover, the parents of the proband of Family Two
were both healthy and paternity was proved, demonstrating
that the mutation in this family is a de novo mutation and also
reaffirming that the 417C>T mutation in Families One and
Two did not result from a founder effect. The age at onset of
symptoms in individuals of Families One and Two carrying
the R124C mutation varied from six to 15 years old. Family
One, a relatively extended family, did not exhibit anticipation
as we described in a previous report [26].
The 417C>T mutation is the most frequent one reported
in  TGFBI;  it  has  been  reported  in  several  ethnic  groups
throughout the world, including Chile [26]. Consequently, it
is not unusual to find a de novo 417C>T mutation in TGFBI.
In  addition,  three  other  different  mutations  have  been
described at the same codon, substituting arginine for three
different amino acids and generating different phenotypes.
These  mutations  are  a  transversion  417C>A  causing  the
substitution for serine (R124S) observed in late onset granular
corneal dystrophy type I [28], a transition 418G>A causing
substitution  for  histidine  (R124H)  observed  in  granular
corneal dystrophy type II (Avellino corneal dystrophy) [5],
and  a  transversion  418G>T  causing  the  substitution  for
leucine  (R124L)  observed  in  a  form  of  granular  corneal
dystrophy type III (Reis-Bucklers corneal dystrophy) [29].
The cause of the high mutation frequency in this codon is
unknown. On the other hand, it is interesting that four different
amino acids in the same position are associated with different
phenotypes. This indicates that Arg124 is critical for normal
TGFBIp function. Structural analyses of the FAS1 domain
predicted that Arg124 residue would be solvent-exposed and
different amino acid substitutions could have very different
effects on TGFBI intermolecular contacts and local protein
structure [30,31]. In fact, it was demonstrated that R124H
substitution abolishes the interaction between TGFBIp and
the widely-expressed protein periostin, but R124L and R124C
did not. This specific effect leads us to presume that the
pathological effects of the substitutions for serine, cysteine,
or leucine may be due to the disruption of some other functions
[32].
On the other hand, the DNA sequencing of the affected
subject of Family Three revealed a heterozygous mutation in
exon  13  (A1762G).  This  mutation  changes  histidine  to
arginine at codon 572 (H572R) located in the fourth FAS
domain; this has only been reported once, in a Thai family
[4]. The age at onset of symptoms of the proband of Family
Three was 21. This is the only case observed in that family,
thus we cannot be sure that this mutation triggers late onset of
the disease, but this at least agrees with the late onset described
by Atchaneeyasakul [4]. Additionally, the phenotype of this
subject was somewhat different than the phenotype described
in subjects with the R124C mutation. For instance, the lattice
lines were thicker than the ones observed in patients with the
R124C mutation and they were also less crowded. Moreover,
in  the  anterior  stroma,  we  also  observed  a  yellowish
discoloration, in agreement with Atchaneeyasakul’s results
[4]. In that report, two patients with LCDI exhibited thick
yellowish corneal plaque in the anterior corneal stroma. Such
yellowish corneal plaque has not been observed in LCD or
any other corneal dystrophy [4]. Unfortunately, we did not
have corneal buttons available to carry out the histopathologic
studies. Since this phenotype is somewhat different than the
one observed in other cases of LCD, it is reasonable to believe
there may be a genetic cause related to the substitution of
histidine for arginine at codon 572 that contributed to the
development of this phenotype.
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TGFBIp  interacts  with  several  extracellular  matrix
(ECM) proteins, including fibronectin, biglycan, decorin, and
several  types  of  collagen  [32].  Most  of  the  mutations
described  in  corneal  dystrophies,  including  A1762G
(H572R),  are  located  in  the  fourth  FAS  domain  [3].
Kannabiran and Klintworth [3] suggested that mutations in
that  conserved  domain  may  alter  normal  TGFBI  protein
folding,  resulting  in  the  accumulation  and  deposition  of
mutant TGFBIp. In fact, TGFBIp deposits have been observed
in  the  cornea  [33-36].  It  has  been  postulated  that  TGFBI
mutations may modify the secondary and tertiary structures
of  TGFBIp.  This  is  supported  by  the  observations  that
TGFBIp may form dimers and tetramers, a characteristic of
many  proteins  capable  of  amyloid  production  [37].  The
question here is why the substitution of histidine for arginine
in position 572 is related to a different color in the anterior
stroma and thicker lattice lines than R124C or other mutations
[26]. The ability of a specific amino acid substitution to induce
amyloid deposition must be related to the location and nature
of  the  substitution,  but  the  role  of  histidine  572  and  the
structural effect of its replacement for arginine on TGFBI
protein  folding  are  not  yet  understood  and  require
experimental exploration.
In summary, we report two new families carrying the
417C>T (R124C) mutation and one family with the mutation
A1762G (H572R) associated with LCDI. The latter mutation
is associated with a distinct phenotype. Further studies are
necessary to understand the normal function of TGFBIp and
the  molecular  mechanisms  underlying  the  variegation  of
phenotypes caused by different mutations.Hospital Clínico de la Universidad de Chile José Joaquín
Aguirre, Santiago de Chile. Our thanks to Dr. Lafayette Eaton
for revising the English.
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